Sanofi’s Real-World COPD Study on Dupilumab: What Investors Should Watch
Sanofi SA (SNY) announced an update on their ongoing clinical study.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The study “Prospective and Retrospective Observational Real-world Study to Characterize Patients With COPD on Dupilumab Long-term Treatment, and Assess Safety and Patient Reported Outcomes” tracks how COPD patients respond to long-term dupilumab use in routine care. It aims to clarify safety, patient experience, and real-world outcomes, which can guide doctors and support future market uptake if results are favorable.
The only treatment examined is dupilumab, a biologic drug already approved for other inflammatory diseases and co-developed by Sanofi and Regeneron. In this setting, it is used as part of standard COPD care, with the study simply observing how patients do over time rather than changing their usual treatment plans.
The study is observational, not a randomized trial, so doctors do not assign patients to different therapies, and there is no placebo group. There is also no blinding, meaning both patients and clinicians know dupilumab is being used, and the main goal is to collect long-term safety data and patient-reported outcomes in a real-world COPD population.
The research follows 350 to 500 COPD patients in France for up to 36 months, combining retrospective data with prospective follow-up. This design helps investors see how durable the drug’s benefits and risks look outside controlled trials, which can strongly influence both market adoption and payer decisions over time.
The study started recruiting after submission on Jan. 13, 2026, with ongoing enrollment as of the last update on Feb. 16, 2026. Primary and final completion dates are not yet posted, but given the 36-month follow-up, key readouts may not emerge for several years, making this a medium to long-term catalyst rather than an immediate trading event.
For Sanofi (SNY), positive real-world COPD data on dupilumab would strengthen its already important respiratory and immunology franchise. It could also expand the drug’s label over time, support higher peak sales, and justify premium pricing versus standard inhaled therapies.
Competitors include AstraZeneca, GSK, and others pursuing biologics and novel inhaled treatments in COPD, so this study helps Sanofi defend and possibly extend its positioning. Strong outcomes could shift investor sentiment toward viewing dupilumab as a multi-disease growth engine, while safety concerns or weak patient-reported benefits would likely weigh on the stock.
Given the observational design, investors should see this as a confirmatory, de-risking effort that complements randomized trials rather than replaces them. The study remains ongoing and updated details are available on the ClinicalTrials portal.
To learn more about SNY’s potential, visit the Sanofi SA drug pipeline page.
